Nausea is the best-known side effect of the GLP-1 peptides. It is also the most misunderstood.
In the studies the FDA reviewed before approving Wegovy (the weight-loss version of semaglutide), nearly half the people on the peptide reported nausea at some point. On placebo, it was about 1 in 6. The difference is real and notable. The reason sits in the brainstem, where one group of cells does two jobs: it processes the "the stomach has food" signal that reads as fullness, and it can fire the nausea response from those same cells. GLP-1 drives both.
When the dose climbs quickly, the brain reads the new signal as too strong before it has learned to tell it apart from a real threat.
That is why nausea concentrates during the dose-up phase, the early weeks when the dose is raised step by step toward its target, and eases after. Most of it is mild to moderate and resolves on its own. The combined data from the FDA-reviewed studies for Wegovy put the median nausea episode at about 8 days, and the rate of new gut side effects leveled off around week 20.
The pattern that does warrant clinical attention is different: nausea that is severe, that persists past the dose-up window, or that comes with vomiting, dehydration, or abdominal pain. That is no longer the expected track. GI-management guidance commonly recommends smaller portions, lower-fat or easier-to-digest meals, and slower eating; the FDA-approved label separately warns not to ignore severe or persistent symptoms. The broader mechanism is covered in The GLP-1 Highway.